NCT Number: NCT02181309
Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers
Study to investigate dose-proportionality over the dosage range 7.5 mg to 22.5 mg, and to assess the effect of food on the pharmacokinetics of meloxicam after a single p.o. administration of 22.5 mg meloxicam oral suspension.
Looking for future studies?
Notify MeKey information
Conditions
Age range
21 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male or female subjects as determined by results of screening
- Age range from 21 to 50 years
- Broca index +/- 20%
- Written informed consent in accordance with Good Clinical Practice and local legislation
Exclusion criteria
- Any finding of the medical examination (including blood pressure, pulse rate and ECG and laboratory value) deviating from normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
- Surgery of the gastro-intestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of orthostatic hypotension, fainting spells and blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within at least 1 month or less than ten half-lives of the respective drug prior to administration
- Use of any drugs which might influence the results of the trial (≤ one week prior to administration or during trial)
- Participation in another trial with an investigational drug within 2 months prior to administration or during trial
- Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on study days
- Alcohol abuse (> 60 g/day)
- Drug abuse
- Blood donation (≥ 100 mL within 4 weeks prior to administration or during the trial)
- Excessive physical activities (within the last week before the study)
- Any laboratory value outside the reference range or clinical relevance
- History of haemorrhagic diatheses
- History of gastrointestinal ulcer, perforation or bleeding
- History of bronchial asthma
For female subjects:
- Pregnancy
- Positive pregnancy test
- No adequate contraception e.g. sterilisation, intrauterine pessary, oral contraceptives
- Inability to maintain this adequate contraception during the whole study period
- Lactating
Treatment and study plan
Meloxicam, medium dose
DrugMeloxicam, high dose
DrugPrimary outcomes
-
Maximum drug plasma concentration (Cmax)
Time frame: up to 96 hours after drug administration
-
Total area under the plasma concentration-time curve from time to administration to infinity (AUC0-infinity)
Time frame: up to 96 hours after drug administration
Secondary outcomes
-
Time to maximum concentration (Tmax)
Time frame: up to 96 hours after drug administration
-
Total area under the plasma drug concentration-time curve from time of administration to the last quantifiable drug (AUC0-tf)
Time frame: up to 96 hours after drug administration
-
Apparent terminal elimination rate constant (λz)
Time frame: up to 96 hours after drug administration
-
Apparent terminal half-life (t1/2)
Time frame: up to 96 hours after drug administration
-
Mean total residence time (MRTtot)
Time frame: up to 96 hours after drug administration
-
Total clearance, divided by f (CL/f)
Time frame: up to 96 hours after drug administration
-
Apparent volume of distribution during the terminal phase, divided by f (Vz/f)
Time frame: up to 96 hours after drug administration
-
Number of patients with adverse events
Time frame: up to 67 days
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
An Open, Randomised, Four-way Crossover Study in Healthy Volunteers to Evaluate the Effect of Food on the Pharmacokinetics of Meloxicam After a Single p.o. Administration of 22.5 mg Meloxicam Oral Suspension and Dose-proportionality Over a Dosage Range of 7.5 mg to 22.5 mg
Important dates
- Study start
- 2002
- Primary completion
- 2002
- First posted
- Jul 3, 2014
- Registry last updated
- Jul 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details